October 25th 2024
Zanubrutinib, obinutuzumab, and venetoclax delivered promising response and survival data for the treatment of patients with mantle cell lymphoma harboring a TP53 mutation.
September 18th 2024
September 16th 2024
The combination of camrelizumab plus gemcitabine, vinorelbine, and pegylated liposomal doxorubicin demonstrated promising efficacy in patients with relapsed/refractory primary mediastinal B-cell lymphoma. The combination also had a manageable safety profile, according to findings from a phase 2 clinical trial.
Read More
CAR T Cell Agents Show Variance in Different Lymphoma Subtypes
July 8th 2020Chimeric antigen receptor T-cell therapy when administered to patients with non-follicular low-grade lymphoma may experience different efficacy outcomes than patients with aggressive B-cell lymphomas, according to a single-institution retrospective data.
Read More
FDA Removes Partial Clinical Hold on Camidanlumab Tesirine Phase 2 Trial
July 6th 2020The FDA has lifted a partial clinical hold placed on the phase 2 clinical trial of camidanlumab tesirine in patients with relapsed or refractory Hodgkin lymphoma after ADC Therapeutics submitted further study information to the FDA.
Read More
FDA Grants Fast Track Designation to Betalutin in R/R Marginal Zone Lymphoma
June 29th 2020"We are very pleased to receive Fast Track Designation for Betalutin in marginal zone lymphoma, which recognizes the clear need for new therapeutic options for patients with advanced marginal zone lymphoma patients who no longer respond to the therapies they have been receiving."
Read More
Tazemetostat Approval Addresses Unmet Need in Relapsed/Refractory Follicular Lymphoma
June 26th 2020In an interview with Targeted Oncology, John P. Leonard, MD, discussed the results of the phase 2 study of tazemetostat, the drug approval for relapsed/refractory follicular lymphoma, and the role of tazemetostat in the community setting.
Read More
sNDA Seeks Expanded Approval of Ibrutinib in Waldenström's Macroglobulinemia
June 23rd 2020"The iNNOVATE study continues to deliver strong clinical evidence supporting the long-term use of ibrutinib plus rituximab across first and second lines of therapy for patients with Waldenström's macroglobulinemia."
Read More
Selinexor Introduces a New Mechanism of Action to Treat Relapsed or Refractory DLBCL
June 22nd 2020In an interview with Targeted Oncology, Michael Schuster, MD, discussed the findings in the phase 2 SADAL study and the importance of the FDA approval of selinexor for the treatment of relapsed/refractory diffuse large B-cell lymphoma.
Read More
FDA Approves Selinexor for R/R Diffuse Large B-Cell Lymphoma
June 22nd 2020Selinexor is now the only single-agent, oral therapy approved for the treatment of patients with R/R DLBCL, and the only nuclear export inhibitor approved by the FDA for use in 2 hematologic malignancies, multiple myeloma and DLBCL.
Read More
Rolling NDA Submitted to FDA for Umbralisib as Treatment of Marginal Zone, Follicular Lymphomas
June 17th 2020“The completion of this New Drug Application submission marks an important milestone in bringing us 1 step closer to providing umbralisib as a potential treatment option for patients with relapsed/refractory marginal zone lymphoma and follicular lymphoma."
Read More
Tafasitamab Plus Lenalidomide Demonstrates Long-Term Efficacy in R/R DLBCL
June 15th 2020“These results, complimented with a favorable safety profile, indicate the utility of this novel immunological combination as a potential treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma."
Read More
Cirmtuzumab Added to Ibrutinib Induces Responses in R/R MCL and CLL
June 6th 2020Compelling objective responses and safety results were demonstrated with the combination of cirmtuzumab and ibrutinib in cohorts of patients with mantle cell lymphoma and chronic lymphocytic leukemia, who were treated in the phase 1b/2 clinical trial.
Read More
Better Outcomes Observed With CAR T-Cell Therapy in Younger Patients With R/R DLBCL
June 6th 2020Chimeric antigen receptor T-cell therapy lead to poor overall survival outcomes it patients who were 75 years or older with relapsed/refractory diffuse large B-cell lymphoma compared with patients aged 70 to 74 years, but progression-free survival was comparable between the 2 groups.
Read More
Phase 1 Study of Venetoclax Combo Sets Stage for Future in Aggressive B-Cell Lymphomas
June 3rd 2020In an interview with Targeted Oncology, Sarah C. Rutherford, MD, discussed the phase 1 findings for the combination of venetoclax plus standard chemoimmunotherapy as treatment of patients with aggressive B-cell lymphomas.
Read More
CAR T-Cell Therapy With Axi-Cel Holds Promise in R/R Indolent NHL
May 30th 2020Interim analysis of the ZUMA-5 study indicates that patients with relapsed or refractory indolent non-Hodgkin lymphoma who were treated with the chimeric antigen receptor T-cell therapy of axicabtagene ciloleucel had high rates of response and demonstrated the agent's manageable safety profile.
Read More
Pembrolizumab Demonstrates Benefit Over BV Regimen in R/R Classical Hodgkin Lymphoma
May 30th 2020Pembrolizumab should be considered the preferred treatment option and the new standard of care in relapsed/refractory classical Hodgkin's lymphoma in patients that have relapsed post autologous stem cell transplant or are ineligible for autologous stem cell transplant.
Read More
FDA Grants Fast Track Designation to Novel Small Molecule Drug in LPL and WM
May 26th 2020"Fast Track Designation for lymphoplasmacytic lymphoma and Waldenstrom’s macroglobulinemia further supports our clinical development strategy to quickly and efficiently provide these patients with an effective therapeutic alternative."
Read More
Addition of Alemtuzumab Improves Responses in Elderly Patients With Peripheral T-Cell Lymphomas
May 19th 2020“This randomized phase III study for the first time provides prospective long-term results on survival and other end points of interest after standard treatment with CHOP in patients with PTCL beyond 60 years who represent the majority of [patients with] PTCL, generally less eligible for more intense therapies like autologous and allogeneic transplantation."
Read More
Trametinib Misses the Mark in BRAF Non-V600-Mutant Solid Tumors and Lymphomas
April 29th 2020"Single-agent trametinib had low rates of clinical activity in patients with heavily pretreated, metastatic cancers harboring non-V600 mutations in BRAF. This contrasts with a number of case reports, largely in melanoma, showing responses in patients with these mutations."
Read More
Community Oncologists Critical to Success of CAR T-cell Therapy in R/R Large B-Cell Lymphoma
April 28th 2020Few options exist for patients with relapsed or refractory large B-cell lymphomas who have already undergone 2 rounds of systemic therapy. New research shows axicabtagene ciloleucel might be a strong option, but community oncologists must play a role in patient identification and post-treatment follow-up.
Read More
FDA Grants RMAT Designation to Tisagenlecleucel in R/R Follicular Lymphoma
April 22nd 2020“This designation supports the advancement of Kymriah, which could potentially address an unmet need in certain patients with follicular lymphoma, as we strive to reimagine medicine at Novartis. These patients are often faced with the burden of several years of various treatments as their disease continues to progress.”
Read More
Indolent Non-Hodgkin Lymphomas Still Require More Durable Treatment Options
April 20th 2020In an interview with Targeted Oncology, Sonali M. Smith, MD, discussed the treatment landscape for patients with indolent non-Hodgkin lymphoma. In particular, she highlighted the data supporting the use of rituximab plus lenalidomide in patients with follicular lymphoma and marginal zone lymphoma.
Read More